208 related articles for article (PubMed ID: 22511311)
21. Comparison of sirolimus-eluting stent and paclitaxel-eluting stent for long-term cardiac adverse events in diabetic patients: the Korean Multicenter Angioplasty Team (KOMATE) Registry.
Kim JS; Lee BH; Ko YG; Choi D; Jang Y; Min PK; Yoon YW; Hong BK; Kwon HM; Ahn MS; Lee SH; Yoon JH; Lee BK; Kim BO; Kim BK; Oh SJ; Jeon DW; Yang JY; Cho JR; Jung JH; Ryu SK;
Catheter Cardiovasc Interv; 2008 Nov; 72(5):601-7. PubMed ID: 18942123
[TBL] [Abstract][Full Text] [Related]
22. The PASEO (PaclitAxel or Sirolimus-Eluting Stent Versus Bare Metal Stent in Primary Angioplasty) Randomized Trial.
Di Lorenzo E; De Luca G; Sauro R; Varricchio A; Capasso M; Lanzillo T; Manganelli F; Mariello C; Siano F; Pagliuca MR; Stanco G; Rosato G
JACC Cardiovasc Interv; 2009 Jun; 2(6):515-23. PubMed ID: 19539255
[TBL] [Abstract][Full Text] [Related]
23. Paclitaxel- versus sirolimus-eluting stents for treatment of ST-segment elevation myocardial infarction: with analyses for diabetic and nondiabetic subpopulation.
Cho Y; Yang HM; Park KW; Chung WY; Choi DJ; Seo WW; Jeong KT; Chae SC; Lee MY; Hur SH; Chae JK; Seong IW; Yoon JH; Oh SK; Kim DI; Park KS; Rha SW; Jang YS; Bae JH; Hong TJ; Cho MC; Kim YJ; Jeong MH; Kim MJ; Park SK; Chae IH; Kim HS;
JACC Cardiovasc Interv; 2010 May; 3(5):498-506. PubMed ID: 20488406
[TBL] [Abstract][Full Text] [Related]
24. Comparable clinical safety and efficacy of biodegradable versus durable polymer paclitaxel eluting stents despite shorter dual antiplatelet therapy: insights from a multicenter, propensity score-matched registry.
Buszman PP; Orlik B; Trela B; Milewski K; Kozlowski M; Pruski M; Drzewiecki J; Peppas A; Granada JF; Kaluza GL; Buszman PE
Catheter Cardiovasc Interv; 2013 Sep; 82(3):E155-62. PubMed ID: 23109067
[TBL] [Abstract][Full Text] [Related]
25. Comparison of 2-year clinical outcomes between zotarolimus-, sirolimus-, and paclitaxel-eluting stents in real life clinical practice.
Kim JH; Park KW; Lim WH; Shin DH; Chae IH; Choi DJ; Kim HS
Catheter Cardiovasc Interv; 2014 Feb; 83(3):349-59. PubMed ID: 24654284
[TBL] [Abstract][Full Text] [Related]
26. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
Dangas GD; Serruys PW; Kereiakes DJ; Hermiller J; Rizvi A; Newman W; Sudhir K; Smith RS; Cao S; Theodoropoulos K; Cutlip DE; Lansky AJ; Stone GW
JACC Cardiovasc Interv; 2013 Sep; 6(9):914-22. PubMed ID: 24050859
[TBL] [Abstract][Full Text] [Related]
27. Clinical and angiographic outcomes in diabetics from the ENDEAVOR IV trial: randomized comparison of zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease.
Kirtane AJ; Patel R; O'Shaughnessy C; Overlie P; McLaurin B; Solomon S; Mauri L; Fitzgerald P; Popma JJ; Kandzari DE; Leon MB
JACC Cardiovasc Interv; 2009 Oct; 2(10):967-76. PubMed ID: 19850257
[TBL] [Abstract][Full Text] [Related]
28. Comparison of six-year clinical outcome of sirolimus- and paclitaxel-eluting stents to bare-metal stents in patients with ST-segment elevation myocardial infarction: an analysis of the RESEARCH (rapamycin-eluting stent evaluated at Rotterdam cardiology hospital) and T-SEARCH (taxus stent evaluated at Rotterdam cardiology hospital) registries.
Simsek C; Magro M; Boersma E; Onuma Y; Nauta S; Daemen J; Gaspersz M; van Geuns RJ; van der Giessen W; van Domburg R; Serruys P
J Invasive Cardiol; 2011 Aug; 23(8):336-41. PubMed ID: 21828397
[TBL] [Abstract][Full Text] [Related]
29. Paclitaxel and sirolimus eluting stents versus bare metal stents: long-term risk of stent thrombosis and other outcomes. From the Western Denmark Heart Registry.
Jensen LO; Tilsted HH; Thayssen P; Kaltoft A; Maeng M; Lassen JF; Hansen KN; Madsen M; Ravkilde J; Johnsen SP; Sørensen HT; Thuesen L
EuroIntervention; 2010 Apr; 5(8):898-905. PubMed ID: 20542774
[TBL] [Abstract][Full Text] [Related]
30. 5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions).
Gada H; Kirtane AJ; Newman W; Sanz M; Hermiller JB; Mahaffey KW; Cutlip DE; Sudhir K; Hou L; Koo K; Stone GW
JACC Cardiovasc Interv; 2013 Dec; 6(12):1263-6. PubMed ID: 24239202
[TBL] [Abstract][Full Text] [Related]
31. Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trial.
Leon MB; Nikolsky E; Cutlip DE; Mauri L; Liberman H; Wilson H; Patterson J; Moses J; Kandzari DE;
JACC Cardiovasc Interv; 2010 Oct; 3(10):1043-50. PubMed ID: 20965463
[TBL] [Abstract][Full Text] [Related]
32. A randomized comparison of sirolimus- versus Paclitaxel-eluting stent implantation in patients with diabetes mellitus.
Lee SW; Park SW; Kim YH; Yun SC; Park DW; Lee CW; Hong MK; Rhee KS; Chae JK; Ko JK; Park JH; Lee JH; Choi SW; Jeong JO; Seong IW; Cho YH; Lee NH; Kim JH; Chun KJ; Kim HS; Park SJ
J Am Coll Cardiol; 2008 Aug; 52(9):727-33. PubMed ID: 18718419
[TBL] [Abstract][Full Text] [Related]
33. Drug-eluting stents for the treatment of ostial coronary lesions: comparison of sirolimus-eluting stent with paclitaxel-eluting stent.
Chen J; Li JJ; Chen JL; Qiao SB; Xu B; Yang YJ; Gao RL; Qin XW; Yuan JQ; Yao M; Wu YJ; Liu HB; Dai J; You SJ
Coron Artery Dis; 2008 Nov; 19(7):507-11. PubMed ID: 18923247
[TBL] [Abstract][Full Text] [Related]
34. Final 5-year outcomes from the Endeavor zotarolimus-eluting stent clinical trial program: comparison of safety and efficacy with first-generation drug-eluting and bare-metal stents.
Kandzari DE; Leon MB; Meredith I; Fajadet J; Wijns W; Mauri L
JACC Cardiovasc Interv; 2013 May; 6(5):504-12. PubMed ID: 23602459
[TBL] [Abstract][Full Text] [Related]
35. Impact of coronary anatomy and stenting technique on long-term outcome after drug-eluting stent implantation for unprotected left main coronary artery disease.
Tiroch K; Mehilli J; Byrne RA; Schulz S; Massberg S; Laugwitz KL; Vorpahl M; Seyfarth M; Kastrati A;
JACC Cardiovasc Interv; 2014 Jan; 7(1):29-36. PubMed ID: 24332416
[TBL] [Abstract][Full Text] [Related]
36. Safety and efficacy of limus-eluting stents and balloon angioplasty for sirolimus-eluting in-stent restenosis.
Ota H; Mahmoudi M; Kitabata H; Torguson R; Chen F; Satler LF; Suddath WO; Pichard AD; Waksman R
Cardiovasc Revasc Med; 2015 Mar; 16(2):84-9. PubMed ID: 25870152
[TBL] [Abstract][Full Text] [Related]
37. Long-term clinical and angiographic outcomes of diabetic patients after revascularization with early generation drug-eluting stents.
Billinger M; Räber L; Hitz S; Stefanini GG; Pilgrim T; Stettler C; Zanchin T; Pulver C; Pfäffli N; Eberli F; Meier B; Kalesan B; Jüni P; Windecker S
Am Heart J; 2012 May; 163(5):876-886.e2. PubMed ID: 22607867
[TBL] [Abstract][Full Text] [Related]
38. Sirolimus-eluting stent versus bare metal stent in diabetic patients: the final five-year follow-up of the DIABETES trial.
Jiménez-Quevedo P; Hernando L; Gómez-Hospital JA; Iñiguez A; SanRoman A; Alfonso F; Hernández-Antolín R; Angiolillo DJ; Bañuelos C; Escaned J; Gonzalo N; Fernández C; Macaya C; Sabaté M;
EuroIntervention; 2013 Jul; 9(3):328-35. PubMed ID: 23518240
[TBL] [Abstract][Full Text] [Related]
39. Comparison between sirolimus- and paclitaxel-eluting stents in complex patient and lesions subsets.
Roy P; Torguson R; Okabe T; Pinto Slottow TL; Steinberg DH; Smith K; Xue Z; Gevorkian N; Satler LL; Kent KM; Suddath WO; Pichard AD; Waksman R
Catheter Cardiovasc Interv; 2007 Aug; 70(2):167-72. PubMed ID: 17503503
[TBL] [Abstract][Full Text] [Related]
40. Randomized evaluation of two drug-eluting stents with identical metallic platform and biodegradable polymer but different agents (paclitaxel or sirolimus) compared against bare stents: 1-year results of the PAINT trial.
Lemos PA; Moulin B; Perin MA; Oliveira LA; Arruda JA; Lima VC; Lima AA; Caramori PR; Medeiros CR; Barbosa MR; Brito FS; Ribeiro EE; Martinez EE;
Catheter Cardiovasc Interv; 2009 Nov; 74(5):665-73. PubMed ID: 19670303
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]